Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofarabine with Cytarabine and G-CSF for Relapsed/Refractory AML
NCT00602225Phase 2Completed
- Sponsor
- University of Washington
- Start
- Dec 2007
- Primary completion
- Mar 2010
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clofarabine in acute myeloid leukemia (AML), sponsored by University of Washington. Primary endpoints: Maximum Tolerated Dose of Clofarabine at 45 days, Dose-limiting Toxicity at 45 days and 1 more. Started Dec 2007; status: completed.
02
Drugs
clofarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00602225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00602225.